This 2012 review by Moen and Stuhr examines the effects of hyperbaric oxygen therapy (HBOT) on cancer progression, focusing on studies from 2004 to 2012. The authors found no evidence that HBOT stimulates tumor growth or recurrence. Instead, HBOT may inhibit tumor growth in certain cancer subtypes, such as breast
This 2018 review evaluates the potential role of ozone therapy as an adjunct in cancer treatment. Preclinical studies suggest that ozone can directly damage tumor cells and enhance the effects of radiotherapy and chemotherapy. Indirect effects observed in animal models include immune modulation and improved tumor oxygenation. Clinical evidence is
This 2004 pilot study evaluated the impact of systemic ozone therapy on tumor oxygenation in 18 patients with advanced cancers. Administered via autohemotransfusion over one week, ozone therapy did not significantly alter overall tumor oxygenation levels. However, it notably reduced the proportion of severely hypoxic tumor regions (pO₂ ≤10 mmHg
A cohort study published in Lancet Oncology (2008) examined the role of tumor hypoxia and angiogenesis markers in predicting the outcome of radical treatments for localized prostate cancer. The study found that high expression levels of VEGF and HIF-1α were linked to shorter biochemical failure-free survival in both radiotherapy and
This study explored the effects of Hyperbaric Oxygen Therapy (HBOT) on lung cancer progression in a murine xenograft model using A549 human lung carcinoma cells. The results showed that HBOT improved tumor hypoxia, suppressed tumor growth, and induced apoptosis in cancer cells. Additionally, HBOT increased the expression of Platelet Endothelial
